INTRODUCTION
Prostate cancer is the most frequently diagnosed malignancy in males and the second leading cause of cancer-related death in men after lung cancer in United States of America [1] . Despite a similar prevalence of latent prostate tumors around the globe, incidence rates for clinical prostate cancer in Western men are 30-50 times higher than those for Asian men and the reason for this difference is unclear. In the United States, prostate cancer accounts for 32 % of all cancer cases in men whereas in Shanghai (China), prostate cancer accounts for less than 1 % of all cancers in men.
However, recent data suggest that prostate cancer rates are increasing [1] . In spite of substantial progress in prostate cancer treatment, the survival rate for advanced stages of this particular cancer has not considerably improved during the past decade [2, 3] . Furthermore, standard treatment preferences for localized prostate cancer (surgical, radiation, and hormonal therapy) are accompanied with complications that often deteriorate patients' quality of life, such as urinary incontinence and sexual dysfunction. Therefore, prostate cancer patients seek complementary and alternative medicine (CAM) treatments in the hope of suppressing or slowing down disease progression to improve the general quality of life. Recent surveys demonstrated that approximately 40 % of prostate cancer patients utilize various CAM modalities as a component of therapy [4] [5] [6] .
Scopoletin (6-methoxy-7-hydroxycomarin) is a phenolic coumarin and an important member of the group of phytoalexins isolated from many plants, and also a prominent coumarin derivative occurring in various plants [7] [8] [9] [10] . It has also been reported to be an active component in the plants such as Erycibe obtusifolia, Aster tataricus and Foeniculum vulgare. These plants have been used in traditional Chinese medicines for the treatment of various diseases with a long history. A variety of biological activities like antiinflammatory, anti-allergy and anti-angiogenesis have been reported for scopoletin [11] [12] [13] [14] . The aim of the current research work was to evaluate the anticancer activity of scopoletin against prostate cancer cells in vitro by studying its effect on apoptosis and cell cycle phase distribution.
EXPERIMENTAL

Chemicals and reagents
Scopoletin was purchased from Sigma Chemical Company (St Louis, MO, USA).Growth medium RPMI-1640 (Hangzhou Sijiqing Biological Products Co, Ltd, China), Minimum Essential Medium (MEM) (Invitrogen Corp, Carlsbad, CA, USA), Fetal Calf Serum (Gibco Corp, Carlsbad, CA, USA), trypsin, penicillin, MTT, streptomycin, DMSO and phosphate buffer saline (PBS) (Sigma) were used in this study. MTT kit was obtained from Roche (USA). Annexin V-FITCPropidium Iodide Apoptosis Detection Kit was purchased from Sigma (USA). All other chemicals and solvents used were of the highest purity grade. Cell culture plastic ware was purchased from BD Falcon (USA).
Cell line
Human prostate carcinoma (LNCaP) cells were procured from the Shanghai Institute of Cell Resource Center of Life Science (Shanghai, China). The cells were grown in a humidified 5 % CO 2 atmosphere at 37 o C in an incubator, and cultured in RPMI-1640 medium supplemented with 10 % heat-inactivated newborn calf serum, 100 IU/mL penicillin and 100 μg/mL streptomycin.
Cell viability assay
The in vitro cytotoxic effect of scopoletin toward human prostate cancer cells (LNCaP) was determined using 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. Cells (5 × 10 3 cells per well) were seeded onto a 96-well plate for 24 h, treated with various concentrations (20, 40, 60, 80 and 100 µM) of Scopoletin, and incubated for an additional 2 days at 37 o C. Thereafter, 10 μL of MTT at a concentration of 5 mg/mL was added to each well, and cells were incubated for an additional 4-6 h. The supernatant was aspirated, and 100 μL of DMSO was added to the wells to dissolve any precipitate present. The absorbance was measured in an ELISA reader (Thermo Molecular Devices Co, Union City, USA) at 570 nm.
Cell inhibition ratio (C) was calculated as in Eq 1.
C (%) = {(Ac At)/Ac}100 ……………………. (1) Cytotoxicity was expressed as the concentration of scopoletin inhibiting cell growth by 50 % (IC 50 ).
Cell cycle analysis by flow cytometry
LNCaP cells (1 × 10 6 ) were seeded in 60-mm dishes and subjected to various concentrations (0, 40, 80, 100 μM) of scopoletin for 48 h. Floating and adherent cells were trypsinized and washed three times with PBS. Cells were incubated in 70 % ethanol at -20 °C overnight, treated with 20 µg/mL RNase A, and stained with 5.0 µg/mL of propidium iodide. Finally the stained cells were analyzed and studied by Flow cytometry at wavelength of 488 nm (FACS Calibur instrument, BD Biosciences, San Jose, CA, USA) equipped with Cell Quest 3.3 software.
Apoptosis detection using Hoechst 33258 staining
LNCaP cells were fixed with 4 % formaldehyde in phosphate buffered saline (PBS) for 30 min before staining with 10 μg/mL of Hoechst 33258 at 37 o C for 20 min. The cells were treated with different concentrations (0, 40, 80, 100 μM) of scopoletin for 48 h. They were then washed once with PBS, and observed under a fluorescence microscope (Nikon). A minimum of 600 cells was counted, and each experiment was performed in triplicate.
Detection of early and late apoptosis, and necrosis by annexin V binding assay
Apoptosis was demonstrated by annexin V binding assay using flow cytometry. Briefly, LNCaP cells were treated with different concentrations (0, 40, 80 and 100 μM) of scopoletin for 48 h. Subsequently, treated and untreated cells were harvested by trypsinization. Harvested cells were then incubated in annexin V-FITC (100ng/mL) and propidium iodide (40 µg/mL), at room temperature for 30 min in dark, and analysed using a FACS Calibur flow cytometer (BD Bioscience).
Western blot analysis
To assess the dose-dependent effect of scopoletin, LNCaP cells were treated for 48 h with various concentrations of scopoletin, (20, 40, 60 and 80 µM to determine the expression levels of cyclin D1 and cyclin B1). Cellular proteins were extracted using a cell lysis buffer containing 75 mM Tris-HCl (pH 7.6), 125 mM NaCl, 0.1 % sodium dodecyl sulfate (SDS), 1 % NP-40, and 1X proteinase inhibitor cocktail (Roche Applied Science, Indianapolis, IN) [11] . Twenty five micrograms of protein was fractionated by electrophoresis through a 20 % SDS polyacrylamide gel, and the proteins were transferred onto a nitrocellulose membrane. The membrane was further incubated with a secondary anti-rabbit antibody conjugated with horseradish peroxidase (Amersham, Arlington Heights, IL), and the specific protein was detected using a chemiluminescent method (Amersham) followed by autoradiography according to manufacturer's instructions. This procedure was repeated for the detection of cyclin D1 and cyclin B1 proteins, using polyclonal rabbit IgG antibodies at a 1:200 dilution (Santa Cruz Biotechnology, Santa Cruz, CA).
Statistical analysis
All statistical analyses were carried out with SPSS® software (version 19.0) based on oneway analysis of variance (ANOVA) and Tukey test. Data are expressed as mean ± SEM, and p < 0.05 was considered significant.
RESULTS
Anti-proliferative activity of scopoletin
The effect of scopoletin treatment on the prostate cancer cell viability is shown in Fig 1. Scopoletin exhibited potent and dose-dependent cytotoxic activity against these cancer cells. The IC 50 value of the extract was calculated to be 65.1 µM. As shown in Figure 1 , 100 µg/mL extract exhibited a very strong anti-proliferative effect at which approximately only 7.91 % of the cells were found live and 92 % dead.
Effect of scopoletin on cell cycle phase distribution in human prostate cancer cells (LNCaP)
The results showed that treatment with different concentrations of scopoletin for 48 h led to an increase in the population of cells in the sub-G0/G1 phase (apoptotic population) (p < 0.01) (Fig 2) . The decline in the S phase population was attended by considerably increased G2/M phase population (p < 0.01) after 48 h treatment compared to the control, suggesting cell cycle arrest at the G2/M phase in scopoletin-treated cells. At 80 and 100 µM scopoletin, the cells had no increment in the G2/M population but increased in the sub-G1 population compared to the control, suggesting that cells were arrested at the G2/M phase followed by significant apoptotic cell death over time.
Hoechst 33258 staining to detect apoptosis in LNCaP cancer cells
Scopoletin treatment resulted in the appearance of cell shrinkage along with membrane blebbing which are characteristic features of cell apoptosis (Fig 3) .
Effect of scopoletin on early and late apoptosis, and necrosis in LNCaP cells
The results of the flow cytometry study with Annexin V/FITC and PI showed that within 48 h . Scopoletin (6-methoxy-7-hydroxycomarin) is a phenolic coumarin and an important member of the group of phytoalexins isolated from many plants.
Studies have shown that scopoletin and its synthetic derivatives exhibit anticancer activity against mammary (MCF-7 and MDA-MB 231) and colon (HT-29) carcinoma cells [28] . In this study we found that scopoletin reduced the expression levels of cyclin D1 in androgendependent manner and caused cell cycle arrest at G2/M phase and induced early and late apoptosis in human prostate cancer cells (LNCaP). As it has been found that the elevated levels of cyclin D1 promote prostate cancer development by reducing its dependence on androgen stimulation [29] . The ability of scopoletin to affect cell cycle regulating molecules is an important finding making it an essential natural product for the development of chemotherapeutic agents against the prostate cancers.
CONCLUSION
The findings of this study indicate that scopoletin exhibits potent anticancer activity by inducing apoptosis, cell cycle arrest and down regulating the expression of cyclin D1 levels in human prostate cancer (LNCaP) cells, thus making it an important natural product for the development of chemotherapeutic agents against prostate cancers and paving a way to elucidate further the mechanism of its action in order to make it more efficient against human prostate cancers. 
